Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO
Eikon Therapeutics Inc., a late-stage cancer drug developer led by Merck & Co. veterans, raised $381.2 million in an upsized US initial public offering.
By Angel Adegbesan ยท Bloomberg
Eikon Therapeutics Inc., a late-stage cancer drug developer led by Merck & Co. veterans, raised $381.2 million in an upsized US initial public offering.